Assignee
NEUROCRINE BIOSCIENCES INC
US·114 granted patents·80 pending applications·1,262 citations·filing 1994–2025
Top patents by PatentIndex Score
194 records- 0198US10160757B2Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)NEUROCRINE BIOSCIENCES INC·Filed 2016·Granted Dec 25, 2018·22 cites·28 claims
- 0297US10952997B2Methods for the administration of certain VMAT2 inhibitorsNEUROCRINE BIOSCIENCES INC·Filed 2020·Granted Mar 23, 2021·11 cites·26 claims
- 0397US10912771B1Methods for the administration of certain VMAT2 inhibitorsNEUROCRINE BIOSCIENCES INC·Filed 2020·Granted Feb 9, 2021·11 cites·15 claims
- 0497US10857148B2Methods for the administration of certain VMAT2 inhibitorsNEUROCRINE BIOSCIENCES INC·Filed 2020·Granted Dec 8, 2020·9 cites·25 claims
- 0597US10857137B2Methods for the administration of certain VMAT2 inhibitorsNEUROCRINE BIOSCIENCES INC·Filed 2020·Granted Dec 8, 2020·11 cites·30 claims
- 0696US11311544B2Treatment of congenital adrenal hyperplasiaNEUROCRINE BIOSCIENCES INC·Filed 2021·Granted Apr 26, 2022·6 cites·28 claims
- 0796US11040029B2Methods for the administration of certain VMAT2 inhibitorsNEUROCRINE BIOSCIENCES INC·Filed 2020·Granted Jun 22, 2021·6 cites·26 claims
- 0896US10993941B2Methods for the administration of certain VMAT2 inhibitorsNEUROCRINE BIOSCIENCES INC·Filed 2020·Granted May 4, 2021·11 cites·29 claims
- 0995US11730739B2Treatment of congenital adrenal hyperplasiaNEUROCRINE BIOSCIENCES INC·Filed 2020·Granted Aug 22, 2023·4 cites·31 claims
- 1095US11311532B2High dosage valbenazine formulation and compositions, methods, and kits related theretoNEUROCRINE BIOSCIENCES INC·Filed 2020·Granted Apr 26, 2022·3 cites·32 claims
- 1195US10919892B2Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)NEUROCRINE BIOSCIENCES INC·Filed 2020·Granted Feb 16, 2021·3 cites·30 claims
- 1295US10906902B2Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)NEUROCRINE BIOSCIENCES INC·Filed 2020·Granted Feb 2, 2021·3 cites·30 claims
- 1395US10906903B2Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)NEUROCRINE BIOSCIENCES INC·Filed 2020·Granted Feb 2, 2021·3 cites·30 claims
- 1495US10065952B2Valbenazine salts and polymorphs thereofNEUROCRINE BIOSCIENCES INC·Filed 2016·Granted Sep 4, 2018·30 cites·17 claims
- 1595US9714246B2[9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating theretoNEUROCRINE BIOSCIENCES INC·Filed 2016·Granted Jul 25, 2017·22 cites·4 claims
- 1695US7419983B2Gonadotropin-releasing hormone receptor antagonists and methods related theretoNEUROCRINE BIOSCIENCES INC·Filed 2007·Granted Sep 2, 2008·38 cites·40 claims
- 1794US12128033B2Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amineNEUROCRINE BIOSCIENCES INC·Filed 2024·Granted Oct 29, 2024·4 cites·18 claims
- 1894US10905690B2Treatment of congenital adrenal hyperplasiaNEUROCRINE BIOSCIENCES INC·Filed 2018·Granted Feb 2, 2021·7 cites·5 claims
- 1994US10874648B2Methods for the administration of certain VMAT2 inhibitorsNEUROCRINE BIOSCIENCES INC·Filed 2017·Granted Dec 29, 2020·11 cites·4 claims
- 2094US9422310B2Gonadotropin-releasing hormone receptor antagonists and methods relating theretoNEUROCRINE BIOSCIENCES INC·Filed 2015·Granted Aug 23, 2016·14 cites·19 claims
- 2194US7176211B2Gonadotropin-releasing hormone receptor antagonists and methods relating theretoNEUROCRINE BIOSCIENCES INC·Filed 2005·Granted Feb 13, 2007·32 cites·20 claims
- 2293US8039627B2Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating theretoNEUROCRINE BIOSCIENCES INC·Filed 2007·Granted Oct 18, 2011·78 cites·2 claims
- 2393US7056927B2Gonadotropin-releasing hormone receptor antagonists and methods relating theretoNEUROCRINE BIOSCIENCES INC·Filed 2004·Granted Jun 6, 2006·49 cites·45 claims
- 2492US8357697B2Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating theretoNEUROCRINE BIOSCIENCES INC·Filed 2011·Granted Jan 22, 2013·43 cites·7 claims
- 2591US11026939B2High dosage valbenazine formulation and compositions, methods, and kits related theretoNEUROCRINE BIOSCIENCES INC·Filed 2020·Granted Jun 8, 2021·5 cites·29 claims
- 2691US6583143B2CRF receptor antagonists and methods relating theretoNEUROCRINE BIOSCIENCES INC·Filed 2001·Granted Jun 24, 2003·35 cites·18 claims
- 2791US5473104AProcess for the preparation of L-carnitineNEUROCRINE BIOSCIENCES INC·Filed 1994·Granted Dec 5, 1995·35 cites·19 claims
- 2890US10851103B2Valbenazine salts and polymorphs thereofNEUROCRINE BIOSCIENCES INC·Filed 2020·Granted Dec 1, 2020·2 cites·27 claims
- 2990US10851104B2Valbenazine salts and polymorphs thereofNEUROCRINE BIOSCIENCES INC·Filed 2020·Granted Dec 1, 2020·2 cites·29 claims
- 3090US10844058B2Valbenazine salts and polymorphs thereofNEUROCRINE BIOSCIENCES INC·Filed 2020·Granted Nov 24, 2020·2 cites·27 claims
- 3190US6531475B1CRF receptor antagonists and methods relating theretoNEUROCRINE BIOSCIENCES INC·Filed 2000·Granted Mar 11, 2003·38 cites·44 claims
- 3289US10940141B1Methods for the administration of certain VMAT2 inhibitorsNEUROCRINE BIOSCIENCES INC·Filed 2020·Granted Mar 9, 2021·7 cites·30 claims
- 3389US6608197B2Gonadotropin-releasing hormone receptor antagonists and methods relating theretoNEUROCRINE BIOSCIENCES INC·Filed 2001·Granted Aug 19, 2003·31 cites·37 claims
- 3488US9782398B2Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereofNEUROCRINE BIOSCIENCES INC·Filed 2015·Granted Oct 10, 2017·23 cites·12 claims
- 3588US7462625B2Gonadotropin-releasing hormone receptor antagonists and methods relating theretoNEUROCRINE BIOSCIENCES INC·Filed 2006·Granted Dec 9, 2008·9 cites·20 claims
- 3688US6384221B1Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related theretoNEUROCRINE BIOSCIENCES INC·Filed 2000·Granted May 7, 2002·24 cites·33 claims
- 3787US11439629B2Methods for the administration of certain VMAT2 inhibitorsNEUROCRINE BIOSCIENCES INC·Filed 2020·Granted Sep 13, 2022·1 cites·32 claims
- 3887US11026931B2Methods for the administration of certain VMAT2 inhibitorsNEUROCRINE BIOSCIENCES INC·Filed 2020·Granted Jun 8, 2021·6 cites·30 claims
- 3987US9718789B2Substituted triazoles and methods relating theretoNEUROCRINE BIOSCIENCES INC·Filed 2016·Granted Aug 1, 2017·3 cites·17 claims
- 4087US7229995B2Gonadotropin-releasing hormone receptor antagonists and methods relating theretoNEUROCRINE BIOSCIENCES INC·Filed 2005·Granted Jun 12, 2007·10 cites·20 claims
- 4186US6544999B2Polymorphs of N-methyl-N-(3-{3-[2- thienylcarbonyl]-pyrazol-[1,5-α]- pyrimidin-9-yl}phenyl)acetamide and compositions and methods related theretoNEUROCRINE BIOSCIENCES INC·Filed 2001·Granted Apr 8, 2003·21 cites·15 claims
- 4286US6346534B1Gonadotropin-releasing hormone receptor antagonists and methods relating theretoNEUROCRINE BIOSCIENCES INC·Filed 2000·Granted Feb 12, 2002·24 cites·38 claims
- 4385US10941159B2Gonadotropin-releasing hormone receptor antagonists and methods relating theretoNEUROCRINE BIOSCIENCES INC·Filed 2019·Granted Mar 9, 2021·1 cites·4 claims
- 4485US10138214B2Substituted triazoles and methods relating theretoNEUROCRINE BIOSCIENCES INC·Filed 2017·Granted Nov 27, 2018·2 cites·20 claims
- 4584US11459305B2Processes for the preparation of uracil derivativesNEUROCRINE BIOSCIENCES INC·Filed 2020·Granted Oct 4, 2022·1 cites·11 claims
- 4684US6664261B2Pyrazolopyrimidines as CRF receptor antagonistsNEUROCRINE BIOSCIENCES INC·Filed 1997·Granted Dec 16, 2003·28 cites·14 claims
- 4783US10336769B2Gonadotropin-releasing hormone receptor antagonists and methods relating theretoNEUROCRINE BIOSCIENCES INC·Filed 2017·Granted Jul 2, 2019·2 cites·1 claims
- 4883US8952161B2Gonadotropin-releasing hormone receptor antagonists and methods relating theretoNEUROCRINE BIOSCIENCES INC·Filed 2013·Granted Feb 10, 2015·4 cites·16 claims
- 4983US6872728B2Gonadotropin-releasing hormone receptor antagonists and methods relating theretoNEUROCRINE BIOSCIENCES INC·Filed 2003·Granted Mar 29, 2005·16 cites·86 claims
- 5083US5959109ACompounds and methods for increasing endogenous levels of corticotropin-releasing factorNEUROCRINE BIOSCIENCES INC·Filed 1996·Granted Sep 28, 1999·28 cites·18 claims
Showing the top 50 of 194 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when NEUROCRINE BIOSCIENCES INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →